P071 LACK OF EFFECT OF CONCOMITANT IMMUNOSUPPRESSANT AND/OR CORTICOSTEROID TREATMENT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: ANALYSIS OF CERTOLIZUMAB PEGOL DATA
J.F. Colombel, Walter Reinisch(Medical University of Vienna), D. Present(Mount Sinai Medical Center), Ralph Bloomfield(AstraZeneca (United Kingdom)), B. Feagan
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Certolizumab Pegol for the Treatment of Crohn's Disease
|New England Journal of Medicine|2007|1.1k
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
|New England Journal of Medicine|2007|1.1k